Ekf Diagnostics Dividends - EKF

Best deals to access real time data!
Level 2 Basic Monthly Subscription for only ~~£62.08~~
Silver Monthly Subscription for only ~~£17.37~~
UK/US Silver Monthly Subscription for only £30.59
VAT not included

Stock Name	Stock Symbol	Market	Stock Type
Ekf Diagnostics Holdings Plc	EKF	London	Ordinary Share

	Price Change	Price Change %	Stock Price	Last Trade
	0.40	0.54%	75.00	16:35:09

Open Price	Low Price	High Price	Close Price	Previous Close
77.00	74.40	77.00	75.00	74.60

more quote information »

Industry Sector
HEALTH CARE EQUIPMENT & SERVICES

Ekf Diagnostics EKF Dividends History

Announcement Date	Type	Currency	Dividend Amount	Period Start	Period End	Ex Date	Record Date	Payment Date	Total Dividend Amount
05/05/2021	Interim	GBX	1.1	01/07/2020	31/12/2020	04/11/2021	05/11/2021	01/12/2021	2.1
14/09/2020	Interim	GBX	1	30/12/2019	30/06/2020	04/11/2020	05/11/2020	01/12/2020	0

Top Dividend Posts

Date	Subject
02/7/2021 08:12	wan: And as a reminder and to put the above into at least some context, from EKF's 2021 – 2024 Growth Strategy Investor Presentation w/c 7 June 2021 - 2. Exploit newly expanded capabilities to meet the demand for contract manufacturing services Leverage relationship with private sector partner to support their diagnostics strategy EKF currently makes kits for their COVID sample collection product in USA, UK and Germany Customer is the largest distribution business in the world Leveraging distribution business to move into ‘home diagnostics’ EKF perfect partner due to manufacturing capabilities in US, Europe and UK EKF also a key regulatory partner Collaborating on new molecular enzyme product to be made in Elkhart Reliant on EKF for all diagnostic advice Increasing demand for kit manufacturing Substantial revenue and EBITDA growth opportunity Page 8 - hTTps://www.ekfdiagnostics.com/res/EKF%20Investor%20Presentation%20June%202021%20Growth%20strategy%202021-2024.pdf Read Full Thread Follow Reply
29/6/2021 08:03	wan: Interesting and encouraging EKF comments in the above interview. I have already been looking (quite closely) at testing for diabetic Ketoacidosis, for which EKF already has a very strong position, but there is real potential for EKF to become the global leader in my view, perhaps especially so with the increasing use of sodium-glucose cotransporter 2 (SGLT2) inhibitors, which apparently raises the risk for diabetic ketoacidosis. I am thus expecting further developments in the specific area of B-HB (perhaps even a tie-up with Renalytix and or its pharma partners?). hTTps://www.ekfdiagnostics.com/beta-hydroxybutyrate.html hTTps://www.ekfdiagnostics.com/diabetic-ketoacidosis-assay-collaboration-between-ortho-clinical-diagnostics-and-ekf-diagnostics.html CLIA waived point of care test - hTTps://www.ekfusa.com/analyzers/stat-site-wb/ Read Full Thread Follow Reply
30/5/2021 11:02	btgman: I want to look a little further at ekf and the Trellus scenario if I may. Ekf use ekf cash to invest in Trellus for the benefit of EKF shareholders. So let's look at £100k investment in EKF say 150,000 shares. This gives 9230 specie shares @65p profit £6k Follow on £100k application in restricted offer assuming 6.5% £6500 of shares received at 65p profit £4062.50 So £10,650 profit. To make £10,650 in the ipo you would need to invest circa £17k Ekf shareholders held 30% of Trellus post raise and potentially receive 3.2% of the ipo. I really do wonder where the benefit really goes to? Perhaps someone could post who got what and how this compares to the EKF shareholders. Going forward the attraction of the specie dividend exists but it is not what I expected it to be. EKF is a solid company with great prospects but the events of the ipo has taken the shine off it morally for me.I get many companies don't allow shareholders to take part but 3.2% of the ipo is too skinny. With a fairer distribution at the ipo it is easy to rectify but Trellus waa the one for me and paying 65% more doesn't sit well as an EKF Trellus holder pre float AIMHO GLA BTG Read Full Thread Follow Reply
14/5/2021 16:28	mirandaj: From December - the facts: https://www.investegate.co.uk/ekf-diagnostics-hldg--ekf-/rns/approval-of-dividend-in-specie/202012140700084652I/ On 11 December 2020 the board of EKF (the "Board") convened and declared a dividend in specie of shares in Trellus to trustees, to be held on trust for the Company's shareholders (the "Dividend"). EKF's investment in Trellus comprises 27,999,999 A Shares of £0.0001 each and 1 golden share of £0.0001 (the "Golden Share"). The Golden Share is the voting share in the capital of Trellus and will be retained by the Company. The Company's shareholders on the register as at close of business on 17 December 2020 ("Relevant EKF Shareholders") will receive one A Share (each a "Dividend Share") for every 16.25 ordinary share held in the Company. Relevant EKF Shareholders will become the beneficial owners of their respective Dividend Shares upon completion of the transfer of the Dividend Shares to Broadway Nominees Limited ("Broadway"), at which time an 'omnibus' share certificate in respect of the Dividend Shares will be issued and held by Broadway, to be held on trust by it on behalf of the Relevant EKF Shareholders for a period of: · 365 days following admission to trading on AIM (or another recognised stock exchange) of the issued share capital of Trellus; or · if the issued share capital of Trellus is not admitted to trading on AIM (or another recognised stock exchange) within two years of the date that the Dividend is settled, two years from the date that the Dividend is settled (the "Lock-up Period"). During the Lock-up Period, Relevant EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Dividend Shares. The A Shares and the Golden Share will, on the earlier of the admission to trading of Trellus on AIM (or another recognised stock exchange) and two years from the date that the Dividend is settled, automatically convert into ordinary shares in Trellus ("Ordinary Shares") on the basis of one Ordinary Share for each A Share or Golden Share held. If Trellus is admitted to trading on AIM (or another recognised stock exchange), the Lock-up Period will continue to apply to the converted Ordinary Shares. All converted Ordinary Shares will rank equally in all respects with all other Ordinary Shares including in respect of voting and dividend rights. The legal title to the Dividend Shares will be held by Broadway as trustee, during the Lock-Up Period. If the A Shares are converted into Ordinary Shares during the Lock-up Period, Broadway will request that Trellus' registrar seeks the voting instructions of the Relevant EKF Shareholders in relation to any shareholder resolution of Trellus and will vote those Dividend Shares in accordance with such instructions as it receives . At the end of the Lock-up Period, Broadway will execute stock transfer forms to transfer the Dividend Shares to the Relevant EKF Shareholders based on a schedule provided by the Company's registrar. Relevant EKF Shareholders will receive a letter informing them of their beneficial holdings of Dividend Shares shortly after the transfer of the Dividend Shares to Broadway. Following the Lock-up Period, Relevant EKF Shareholders will receive individual certificates in respect of their Dividend Shares. The anticipated timetable for the Dividend is: EKF ordinary shares marked as ex rights Start of trading on 16 December 2020 Record date for the distribution of the Dividend Close of business on 17 December 2020 Transfer of shares in Trellus to Broadway as trustee 18 December 2020 The undertaking in relation to Broadway acting as legal holder of the Dividend Shares can be accessed via the investor section of the Company's website. Read Full Thread Follow Reply
09/5/2021 13:10	wan: Based on the most recent trading update & expansion of supply agreement, which I believe to be conservative, what are we, or indeed the Sunday Times journalist, missing from what we have been guided? - EKF Diagnostics Holdings PLC Trading update & Expansion of supply agreement 30/03/2021 Further to the announcement on 12 January 2021 , trading in the first quarter was materially ahead of management expectations. With subsequent orders under this expanded global contract expected to make a considerable contribution throughout the current financial year and beyond, the Board is confident that trading for the year ending 31 December 2021 will be significantly ahead of already upgraded management expectations. Julian Baines, CEO of EKF, said: "We are delighted to continue our relationship with our partner in the private sector and support their global staff testing initiative with the expansion of our supply agreement for collection kits. The contract has gone from covering the UK to supporting our partner's global staff testing programme. We expect this partnership to contribute materially to our 2021 performance and are confident in delivering results significantly ahead of current management forecasts which were most recently upgraded in January this year." Full release - hTTps://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Trading-update-Expa/84696446 Subsequently N-1 Singer analyst Chris Glasper upgraded his forecast for December 2021 revenues to £64 million and adjusted pre-tax profit to £15.5 million. From the recent Presentation - 2021 Outlook The Board is confident that trading for the year ending 31 December 2021 will be significantly ahead of already upgraded management expectations throughout 2021 • 30 March 2021 announced the signing of a multi-million dollar global supply contract with a private sector partner • Core business experiencing a strong recovery, particularly in the US McKesson OEM of DiaSpect Tm expected to return to pre-pandemic sales expectations • Customer base intact but was impacted by closure of physicians’ offices to medical sales representatives throughout 2020 • Placement of analysers into setting expected to return to 2020 levels (c. 100 per month) during 2021 Continued demand for PrimeStore MTM tubes and bulk medium • £2.49m of orders to Ireland in Q1 (versus £5.2m in 2020) • £3m+ of orders in-house from Concepta, Oncologica and PHE Manchester Orders of PBS (phosphate-buffered saline) to exceed £2.4m in Q1 • Two-year global supply contract with a major international brand customer for regular staff testing and home-use • Manufactured at sites in the US, UK and Germany Trellus Health flotation expected in H1 2021 to generate further value for holders hTTps://www.ekfdiagnostics.com/res/EKF%20Diagnostics%20EoY%20presentation%202020.pdf Whilst I am sure there will be a combination of both headwinds and tailwinds, EKF's management were confident enough to upgrade the whole year (and adding materially beyond 2021). Not to mention that parts of the globe, where I assume said private sector partner also has staff, are not as fortunate as we are in terms of vaccine availability/roll-outs and low infection rates, hence the likes of Amazon is expanding their testing sites 'globally' - Amazon’s COVID-19 testing lab processes more than 1 million tests for front-line employees February 11, 2021 “Our team came together with a mission to rapidly build an in-house COVID-19 testing lab because we knew it was a final step, on top of all our onsite COVID-19 precautions, to ensure the health and safety of our front-line employees,” said Cem Sibay, Vice President, Amazon. “We built this lab to scale so that we can offer regular testing to all Amazon front-line employees. Over 500,000 employees have already been voluntarily tested and we are continuing to expand to over a thousand COVID-19 testing sites globally.” hTTps://www.aboutamazon.com/news/operations/amazons-covid-19-testing-lab-processes-more-than-1-million-tests-for-front-line-employees I would also suggest that testing will remain a critical factor/requirement for the likes of Amazon as we enter the flu seasons (is it flu or COVID?). And beyond COVID-19 (hopefully and eventually) Amazon's testing infrastructure and capabilities will no doubt be put to further good use. Read Full Thread Follow Reply
09/5/2021 04:08	travestor: Started so well, heyho i was toying with a top up, might just get a bargain now: Apply the sniff test to this Covid winner Sabah Meddings Sunday May 09 2021, 12.01am BST, The Sunday Times It has 1.3 million staff, warehouses worldwide and a market value of $1.7 trillion. Can you name this company? You will not find the answer in March’s stock exchange announcement from EKF Diagnostics, in which it boasted about a multimillion-dollar contract with a mystery global partner in the private sector, sending its share price over 5 per cent. However, City speculation suggests that the AIM-listed EKF has scored a two-year deal with Amazon. EKF is not at liberty to confirm, but this deal is expected to be worth many millions. Not bad going for a company that was a penny stock five years ago. EKF, led by chairman Christopher Mills, a small-cap veteran who made his name at JO Hambro in the 1990s, specialises in “point of care” tests where physicians can find out in real time whether patients are suffering from conditions such as anaemia, diabetes or sepsis. It is also a “Covid stock”. EKF makes sample collection kits that keep the virus “inactivated” (meaning it is no longer able to infect anyone) in the collection tube — avoiding contamination while preserving the crucial RNA macromolecule. EKF supplies these testing kits to Public Health England and the Irish government, along with private customers. Shares in the company have risen more than 220 per cent since the middle of March last year, closing on Friday at 70.40p and giving EKF a value of £320.3 million. So far, so good. However, the City was spooked slightly last month when Mills, 68, sold almost four million shares at 80p each, cutting his stake from 29.7 per cent to 29 per cent (he first bought in at 9p). The stock has drifted 13 per cent since then. Sources suggest that Mills has a long-term plan to diversify his portfolio, and that he is likely to sell more if the good news continues. Elsewhere, the longevity of EKF’s uplift is in question. Covid-related sales accounted for 40 per cent of last year’s revenues of £65.3m — up 45 per cent — but beyond Covid, sales have fallen short. EKF’s clinical chemistry, diabetes and haematology divisions all declined as patients stayed away from doctors — reducing demand for its screening products. SPONSORED EKF has more than £30 million of cash and investments. It is launching a product that can test rapidly for sepsis, which kills 48,000 a year in the UK, and it is expected that it will soon launch a plan to double core earnings over the next three to four years. The question is whether its share price will get a dose of reality once the demand for testing is over. For now, investors would be wise to follow Mills and take profits. Read Full Thread Follow Reply
21/4/2021 12:04	wan: The following has been on my mind for a while and provides further food for thought - Lateral flow tests are dependant upon a number of factors in terms of performance, not least by the preparation/make up of the buffer solution. This is quite often in the form of a Phosphate Buffer Saline (PBS), which is used for the sample dilution (and of course sample collection/protection). So, the buffer solution and composition represents a critical element of the test, which can also affect the accuracy of the test. Recall that EKF has commenced production of PBS for collection kits - Additional production lines for Phosphate Buffered Saline (PBS) established Q1 2021 at Boerne, South Bend, Barleben and Cardiff sites Orders of PBS (phosphate-buffered saline) to exceed £2.4m in Q1 • Two-year global supply contract with a major international brand customer for regular staff testing and home-use • Manufactured at sites in the US, UK and Germany hTTps://www.ekfdiagnostics.com/res/EKF%20Diagnostics%20EoY%20presentation%202020.pdf For reference - 30 March 2021 Trading update & Significant expansion of supply agreement for COVID-19 sample collection kits Private sector partnership with EKF for global staff testing programme Under this new multiyear global supply contract, EKF will now support its partner's world-wide staff testing initiative, with orders being fulfilled from EKF's production sites in the UK, Germany and the United States. The Company expects orders from the expanded agreement to reflect EKF's increased contribution to their partner's global testing programme, and therefore this agreement is expected to facilitate future orders which will contribute materially to 2021 performance and beyond. The contract has an initial term of two years after which it renews automatically on a monthly basis. Further to the announcement on 12 January 2021 , trading in the first quarter was materially ahead of management expectations. With subsequent orders under this expanded global contract expected to make a considerable contribution throughout the current financial year and beyond, the Board is confident that trading for the year ending 31 December 2021 will be significantly ahead of already upgraded management expectations. hTTps://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Trading-update-Expa/84696446 There is obviously differences between PBS for sample collection/collection kits and that for a lateral flow test, but I had been wondering about the difference in terms of the manufacturing processes for each, which don't seem miles apart from my layman perspective, especially as the required lab facilities in terms of sterile environment/product are in place. It would certainly fit well with the supplying of the picks & shovels terminology. Anyway, as I said at the beginning, it's only food for thought at this stage. Read Full Thread Follow Reply
10/4/2021 06:37	wan: It looks like JUSTIN URQUHART STEWART FOR THE DAILY MAIL, likes EKF, but he hopes he can buy it cheaper, but he clearly does not fully appreciate what else is under EKF's bonnet (nor appreciates who EKF's private partner is and how that relationship might evolve, or perhaps even hoping it's not actually revealed anytime soon). Time will tell, but he might do well to read Hastings excellent and most recent coverage - EKF - A HEALTHY INVESTMENT - 09/03/21 Whilst the huge level of success from its PrimeStore offering has been the key driver of EKF’s share price over the last year, there continues to be much more on offer here. Full article - hTTps://martinflitton1.wixsite.com/privatepunter/post/ekf-a-healthy-investment-09-03-21 The Daily Mail piece - MR MONEY MAKER: EKF Diagnostics has the kit to give your portfolio a shot in the arm By JUSTIN URQUHART STEWART FOR THE DAILY MAIL PUBLISHED: 21:50, 9 April 2021 Any suggestions? So I like to look for history of success from the team over some years. EKF Diagnostics certainly has this, but the price is quite full. I would prefer to keep it on the watch list and wait for a pullback, which will be coming in the not too distant future. Full story - hTTps://www.thisismoney.co.uk/money/investing/article-9454835/MR-MONEY-MAKER-EKF-Diagnostics-boost-portfolio.html As I said previously, there are indeed other reasons to be bullish on EKF (more of which later), and thus in my view there will likely be plenty of investors in the wings hoping to buy before upgrades (given the current broker conservatism), or on any weakness. JUS is clearly one one of those, and to a degree, talking it down to help achieve that. Importantly though, and as a consequence, any meaningful weakness (if it materialises) might be very short lived! Read Full Thread Follow Reply
03/3/2021 07:36	wan: An interesting comparison - Last years Notice of FY Results announcement contained the following description - About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com ) EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers. hTTps://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Notice-of-Results/81906145 Todays announcement contains the following description - About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com ) EKF Diagnostics Holdings plc specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the USA for a variety of life science products. In 2020, EKF developed a range of COVID-19 testing products including PrimeStore MTM, an FDA-approved and CE marked sample containment device that allows the safe handling, transportation and analysis of test swabs and samples, which it manufactures under licence, and COVID-SeroKlir, a leading ELISA-based antibody test from Kantaro Biosciences that provides a precise measurement of COVID-19 IgG antibodies. hTTps://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Notice-of-Results/84481970 In my opinion only, this further supports my view that PrimeStore products will become core EKF products i.e. in constant use for the foreseeable (as perhaps exemplified by SBI's expansion in the US), and in that I also include country surveillance and preparedness. Read Full Thread Follow Reply
16/2/2021 07:38	wan: Melody...the relevant announcement/details - On 11 December 2020 the board of EKF (the “Board”) convened and declared a dividend in specie of shares in Trellus to trustees, to be held on trust for the Company's shareholders (the "Dividend"). EKF’s investment in Trellus comprises 27,999,999 A Shares of £0.0001 each and 1 golden share of £0.0001 (the "Golden Share"). The Golden Share is the voting share in the capital of Trellus and will be retained by the Company. The Company's shareholders on the register as at close of business on 17 December 2020 ("Relevant EKF Shareholders") will receive one A Share (each a "Dividend Share") for every 16.25 ordinary share held in the Company. Relevant EKF Shareholders will become the beneficial owners of their respective Dividend Shares upon completion of the transfer of the Dividend Shares to Broadway Nominees Limited (“Broadway”), at which time an ‘omnibus’ share certificate in respect of the Dividend Shares will be issued and held by Broadway, to be held on trust by it on behalf of the Relevant EKF Shareholders for a period of: 365 days following admission to trading on AIM (or another recognised stock exchange) of the issued share capital of Trellus; or if the issued share capital of Trellus is not admitted to trading on AIM (or another recognised stock exchange) within two years of the date that the Dividend is settled, two years from the date that the Dividend is settled (the “Lock-up Period”). During the Lock-up Period, Relevant EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Dividend Shares. Full details - hTTps://www.ekfdiagnostics.com/approval-of-dividend-in-specie-of-investment-in-trellus-health.html Read Full Thread Follow Reply

Advertise Here

Your Recent History

LSE

EKF

Ekf Diagno..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20210801 14:31:07